Hypertrophic Cardiomyopathy (HCM)
We recommend
INFOGRAPHIC: Mavacamten in the treatment of obstructive hypertrophic cardiomyopathy
Obstructive hypertrophic cardiomyopathy (HCM) is most commonly caused by disorders of cardiac muscle proteins. How does targeted treatment for this disease work? We bring a concise, graphically processed overview of the efficacy and mechanism of action of the first selective cardiac myosin inhibitor.
Updated Recommendations of the European Society of Cardiology for the Treatment of HCM
Newly published guidelines by the European Society of Cardiology (ESC) bring several updates in the…
Long-term Efficacy and Safety of Mavacamten in the Treatment of Obstructive HCM
Interim results of the MAVA-LTE study provide the latest data on the long-term safety and efficacy…
Articles on this topic
Mavacamten in the Treatment of HCM in Patients Referred for Septal Reduction
Extended 56-week follow-up of patients with hypertrophic cardiomyopathy (HCM) resistant to…
Pharmacological Profile of Mavacamten and Key Studies of Its Use in HCM Treatment
A new addition to the treatment options for hypertrophic cardiomyopathy, approved for use in…
INFOGRAPHIC: Diagnosis and Monitoring of Patients with Hypertrophic Cardiomyopathy – Current Guidelines
What examinations should be conducted when suspecting hypertrophic cardiomyopathy, a…
Hypertrophic Cardiomyopathy: When Bigger Does Not Mean Better
Hypertrophic cardiomyopathy (HCM) is a hereditary disease that, in some patients, proceeds…
Why does the heart enlarge? Myosin mutation and hypertrophic cardiomyopathy may be the culprits
The genetic basis of hypertrophic cardiomyopathy was discovered only about a quarter-century…
Subscribe
Conferences news
Go to records
Go to records
Most read on this topic
- Hypertrophic Cardiomyopathy: When Bigger Does Not Mean Better
- Why does the heart enlarge? Myosin mutation and hypertrophic cardiomyopathy may be the culprits
- Pharmacological Profile of Mavacamten and Key Studies of Its Use in HCM Treatment
- INFOGRAPHIC: Diagnosis and Monitoring of Patients with Hypertrophic Cardiomyopathy – Current Guidelines
- INFOGRAPHIC: Mavacamten in the treatment of obstructive hypertrophic cardiomyopathy
- Updated Recommendations of the European Society of Cardiology for the Treatment of HCM
Journal on this topic
Related topic